posit
singlestrand
rna
viru
member
famili
arterivirida
order
nidoviral
like
coronavirida
eav
caus
respiratori
reproduct
diseas
equid
although
two
vaccin
avail
vaccin
coverag
equin
popul
larg
insuffici
prevent
new
eav
outbreak
around
world
studi
present
highthroughput
vitro
assay
suitabl
test
candid
antivir
molecul
equin
dermal
cell
infect
eav
use
assay
identifi
three
molecul
impair
eav
infect
equin
cell
broadspectrum
antivir
nucleosid
analog
ribavirin
two
compound
previous
describ
inhibitor
dihydroorot
dehydrogenas
dhodh
fourth
enzym
pyrimidin
biosynthesi
pathway
molecul
effect
suppress
cytopath
effect
associ
eav
infect
strongli
inhibit
viral
replic
product
infecti
particl
sinc
ribavirin
alreadi
approv
human
small
anim
sever
dhodh
inhibitor
advanc
clinic
trial
result
open
new
perspect
manag
eav
outbreak
keyword
antivir
activ
equin
arter
viru
dihydroorot
dehydrogenas
pyrimidin
biosynthesi
inhibitor
ribavirin
authorfund
right
reserv
reus
allow
without
permiss
virus
rna
genom
infect
anim
plant
domin
eukaryot
virom
divers
deleteri
effect
previou
work
explor
eav
inhibitor
propos
use
morpholino
peptideconjug
morpholino
oligom
specif
design
eav
genom
therapi
impair
viral
replic
howev
promis
therapi
easili
applic
use
vivo
larg
anim
hors
although
two
effect
eav
vaccin
avail
sinc
proport
hors
vaccin
eav
equin
popul
remain
insuffici
control
diseas
think
complementari
approach
use
antivir
molecul
would
ideal
complement
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
vaccin
reduc
viral
spread
equin
structur
contain
eav
outbreak
support
recent
studi
show
global
strategi
base
vaccin
combin
drug
therapi
enhanc
protect
footandmouth
diseas
studi
develop
throughput
cellviabl
assay
base
infect
equin
dermal
cell
took
advantag
new
assay
explor
potenti
broadspectrum
antivir
replic
multipl
direct
indirect
mechan
particular
ribavirin
inhibit
inosin
monophosph
dehydrogenas
impdh
key
enzym
catalyz
first
commit
limit
step
de
novo
synthesi
guanin
nucleotid
impdh
inhibit
interfer
product
gtp
necessari
synthesi
viral
rna
molecul
mechan
report
direct
inhibit
viral
polymeras
lethal
mutagenesi
viral
genom
besid
ribavirin
also
test
two
newli
design
bsa
target
pyrimidin
biosynthesi
pathway
name
two
molecul
inhibitor
dihydroorot
dehydrogenas
dhodh
fourth
ratelimit
enzym
de
novo
pyrimidin
biosynthesi
pathway
shown
impair
replic
mani
differ
positivestrand
negativestrand
rna
virus
studi
shown
first
time
ribavirin
pyrimidin
biosynthesi
inhibitor
inhibit
eav
equin
dermal
cell
cultur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
result
eav
cytopath
viru
studi
took
advantag
specif
develop
micropl
assay
identif
eav
inhibitor
cellular
model
select
ed
cell
line
origin
equin
dermi
thu
match
host
specif
eav
setup
vitro
assay
first
analyz
prolifer
noninfect
ed
cell
plate
determin
number
viabl
cell
cultur
well
quantifi
atp
parallel
number
metabol
activ
live
cell
assay
perform
use
commerci
reagent
base
principl
firefli
luciferas
luminesc
proport
depend
atp
concentr
celltiterglo
luminesc
cell
viabil
assay
promega
noninfect
cell
atp
level
increas
first
h
consequ
cellular
prolifer
plateau
h
cell
cultur
reach
confluenc
figur
experi
perform
use
cell
cultur
infect
bucyru
strain
eav
multipl
infect
moi
shown
figur
number
genom
copi
increas
log
first
h
log
h
postinfect
figur
final
show
infecti
viral
particl
also
produc
ed
cell
inde
least
pfuml
detect
supernat
infect
cultur
hpi
figur
therefor
ed
cell
repres
excel
vitro
model
eav
infect
quantif
atp
level
cultur
well
conveni
way
measur
cytopath
effect
associ
viral
growth
previou
studi
broadspectrum
antivir
molecul
show
ribavirin
inhibit
replic
differ
nidovirus
includ
arterivirida
porcin
reproduct
respiratori
syndrom
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
viru
prrsv
thu
test
antivir
effect
ribarivin
eav
use
cellviabl
assay
describ
prerequisit
first
evalu
cytotox
ribavirin
ed
cell
cell
incub
ribavirin
differ
concentr
number
viabl
cell
determin
h
without
treatment
h
without
treatment
signific
cell
death
report
lower
concentr
ribavirin
compar
initi
number
viabl
cell
seed
cultur
well
figur
howev
ribavirin
clearli
cytostat
concentr
cell
viabil
decreas
treat
cell
ribavirin
respect
figur
half
maxim
toxic
concentr
tc
concentr
kill
cell
cultur
estim
ribavirin
test
effect
ribavirin
vitro
eav
infect
model
noncytotox
concentr
rang
shown
figur
atp
quantif
infect
cultur
well
h
show
cell
aliv
absenc
ribavirin
oppos
presenc
drug
viabil
infect
cell
treat
ribavirin
figur
result
use
calcul
half
maxim
inhibitori
concentr
ic
ribavirin
estim
ie
demonstr
ribavirin
abl
protect
ed
cell
associ
cytopath
effect
also
interest
explor
antivir
capac
two
new
bsa
impair
viral
replic
inhibit
de
novo
pyrimidin
biosynthesi
host
cell
use
vitro
eav
infect
assay
test
first
cytotox
compound
treatment
show
sign
cytotox
ed
cell
cell
viabil
treatment
cytostat
effect
observ
expect
class
drug
figur
result
indic
tc
ed
cell
explor
cytoprotect
effect
two
compound
eavinfect
cultur
differ
concentr
result
show
h
cultur
viabil
infect
ed
cell
reach
treat
treat
concentr
figur
ic
estim
ie
effect
sinc
viabil
ed
infect
cell
treat
highest
concentr
figur
ic
ie
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
result
show
cell
cultur
treat
pyrimidin
biosynthesi
inhibitor
exhibit
cytopath
effect
associ
eav
infect
suggest
eav
replic
also
impair
verifi
ribavirin
actual
block
eav
replic
viral
genom
copi
quantifi
hpi
cultur
supernat
infect
ed
cell
treat
compound
differ
concentr
analyz
rtqpcr
result
show
ribavirin
significantli
reduc
number
eav
genom
copi
cultur
supernat
compar
untreat
infect
cell
figur
eav
replic
total
block
determin
comparison
initi
inoculum
quantifi
hpi
result
confirm
ribavirin
impair
eav
replic
ed
cell
thu
explain
posit
effect
cell
surviv
parallel
also
measur
viral
genom
copi
present
supernat
infect
cell
treat
pyrimidin
biosynthesi
inhibitor
expect
reduc
number
viral
genom
copi
cultur
supernat
treat
concentr
fulli
block
eav
replic
figur
rank
three
molecul
character
eav
inhibitor
studi
calcul
molecul
select
index
si
correspond
tc
ic
ratio
thu
reflect
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
activ
drug
take
account
cytotox
effect
tc
ic
valu
determin
dose
respons
experi
present
figur
si
valu
ribavirin
respect
conclus
confirm
ribavirin
lead
molecul
interest
develop
potenti
antivir
therapi
eav
easili
grown
vitro
ensur
repeat
reproduc
ht
oppos
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
exampl
upper
respiratori
tract
mucos
explant
system
goal
studi
develop
highthroughput
screen
assay
evalu
antivir
properti
mode
action
candid
compound
eav
proof
concept
identifi
ribavirin
inhibitor
eav
equin
cell
thu
pave
way
develop
therapi
eav
toxic
ed
cell
test
concentr
among
three
molecul
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
infect
model
fulli
compat
ht
autom
flexibl
assay
appropri
screen
compound
librari
biolog
product
serum
nanobodi
cytokin
etc
allow
explor
treatment
combin
eav
infect
thank
assay
demonstr
ribavirin
effect
reduc
replic
eav
hors
cell
concentr
toxic
support
report
show
ribavirin
effici
inhibit
replic
multipl
nidovirus
coronavirida
arterivirida
famili
merscov
pprsv
respect
addit
show
dhodh
inhibitor
also
impair
replic
eav
outperform
ribavirin
assess
higher
select
index
known
america
equin
practic
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
b
c
figur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
b
c
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
